What Is One of the Best Pharmaceutical Stocks to Buy Right Now?
Pharma's Next Breakout Play Revealed
Forget chasing yesterday's winners—the real opportunity lies in identifying tomorrow's healthcare titans before Wall Street catches on. While retail investors pile into overhyped biotech names, smart money targets established players with pipeline depth and regulatory moats.
The Contenders: Big Pharma vs Biotech
Major pharmaceuticals offer stability with dividend cushions, while emerging biotech stocks promise explosive growth—if their clinical trials don't implode. The sweet spot? Companies bridging both worlds with proven revenue streams and groundbreaking therapies in late-stage development.
Pipeline Power: What Separates Winners From Has-Beens
Look beyond current blockbusters to patent cliffs and Phase III catalysts. Companies with diversified therapeutic areas—oncology, neurology, rare diseases—spread risk while maximizing upside. The ideal candidate boasts both immediate cash flow and pipeline fireworks.
Regulatory Roulette: Navigating the FDA Maze
Approval delays can crater valuations overnight. Savvy investors prioritize companies with strong regulatory track records and transparent communication strategies. Because nothing hurts more than watching a 'sure thing' get delayed for 'additional data requests'.
Financial Fitness: Beyond the Balance Sheet
Strong cash reserves matter, but deployment strategy matters more. Companies aggressively reinvesting in R&D while maintaining shareholder returns strike the elusive balance between growth and stability. Unlike certain tech stocks, pharma actually needs to deliver tangible results.
The Verdict: Playing Defense While Scoring Offense
In a sector where FDA decisions move markets faster than earnings reports, the best pharmaceutical stock combines innovation with execution—a rare breed that treats both patients and portfolios. Just remember: if your broker's recommendation rhymes with 'buy everything', maybe question their commission structure.
A blockbuster developer
Some pharmaceutical companies dream of developing and launching one blockbuster drug that will sustain it. Going by full-year 2024 sales, AbbVie had no fewer than 12 of them, a lineup that includes its top seller Skyrizi and the well-known Botox. Collectively, that dozen brought in net revenue of nearly $47 billion.
Image source: Getty Images.
Patients across various therapeutic areas are constantly being prescribed medicines made by AbbVie. In the company's most recently reported quarter, net revenue ROSE by nearly 7% year over year (to $15.4 billion). That's an impressive rate given the company's size and longevity. Non-GAAP (adjusted) net income per share rose more meaningfully, advancing by 12% to $2.97.
AbbVie's profit can swing around some -- this isn't unusual, given that large pharmaceutical companies are always staring down from patent cliffs, and development pipelines are expensive. But it consistently manages to make a buck and throw off plenty of cash while doing it. Over the past five years, its free cash FLOW has ranged from almost $16.8 billion to $24.2 billion.
Pharmaceutical royalty
That's a lot of scratch, and AbbVie is always willing to share some of it in the FORM of shareholder dividends. In fact, the company is a Dividend King, having raised its dividend for at least 50 consecutive years, and a well-paying one at that. Its quarterly payout currently stands at $1.64 per share, which yields just under 3% -- well above the 1.2% average of all component stocks of theindex.
In any industry, the combination of a solid product lineup and a high payout is irresistible. In pharmaceuticals, it's very rare. AbbVie is a special stock, and to me it's undoubtedly a buy candidate.
